Shopping Cart
- Remove All
- Your shopping cart is currently empty
NCGC00135472 (DRV1 (GPR32) agonist C2A) is a human Resolvin DI receptor DRV1 agonist with pro-catabolic properties that activates the human soluble protein D1 receptor DRV1/GPR32 receptor in beta-blocker and cAMP assays with EC50s of 0.37 uM and 0.05 uM, respectively.NCGC00135472 induces in cells overexpressing recombinant DRV1 rapid impedance changes that stimulate phagocytosis of serum-treated zymoglycans.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $350 | In Stock | |
5 mg | $828 | In Stock | |
10 mg | $1,130 | In Stock | |
25 mg | $1,590 | In Stock | |
50 mg | $1,980 | In Stock | |
100 mg | $2,500 | In Stock | |
500 mg | $4,900 | In Stock |
Description | NCGC00135472 (DRV1 (GPR32) agonist C2A) is a human Resolvin DI receptor DRV1 agonist with pro-catabolic properties that activates the human soluble protein D1 receptor DRV1/GPR32 receptor in beta-blocker and cAMP assays with EC50s of 0.37 uM and 0.05 uM, respectively.NCGC00135472 induces in cells overexpressing recombinant DRV1 rapid impedance changes that stimulate phagocytosis of serum-treated zymoglycans. |
Targets&IC50 | β-arrestin:0.37 μM, cAMP:0.05 μM |
In vitro | We implemented a high-throughput screening of small molecule libraries and identified chemotypes that activated recombinant DRV1, including NCGC00135472 (C2A). NCGC00135472 (100 nM to 10 mM) dose-dependently elicited rapid changes in impedance with CHO-DRV1.[1] |
Alias | NCGC-00135472, NCGC 00135472, DRV1 (GPR32) agonist C2A, C2A |
Molecular Weight | 364.35 |
Formula | C20H14F2N4O |
Cas No. | 862811-76-5 |
Smiles | CC1=C(N=C2N=CC=CN12)C1=CC(NC(=O)C2=CC=C(F)C(F)=C2)=CC=C1 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||
Solubility Information | DMSO: 1.8 mg/mL (5.0 mM) | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.